5-溴-3,4-二氢-1H-异喹啉-2-羧酸叔丁酯 | 215184-78-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 5-溴-3,4-二氢-1H-异喹啉-2-羧酸叔丁酯
• 中文别名: 5-溴-1,2,3,4-四氢异喹啉盐酸盐(带BOC)；5-溴-1,2,3,4-四氢异喹啉盐酸盐；N-BOC-5-溴-1,2,3,4-四氢异喹啉；5-溴-3,4-二氢异喹啉-2(1H)-甲酸叔丁酯；2-BOC-5-溴-1,2,3,4-四氢异喹啉；2-BOC-5-溴-3,4-二氢-2(1H)-异喹啉；5-溴-1,2,3,4-四氢异喹啉+BOC；5-溴-1,2,3,4-四氢异喹啉-2(1H)-羧酸叔丁酯；5-溴-1,2,3,4-四氢异喹啉氢溴酸
• 英文名称: tert-butyl 5-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate
• 英文别名: tert-butyl 5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylate；t-butyl 5-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate；5-bromo-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester
• CAS: 215184-78-4
• 化学式: C₁₄H₁₈BrNO₂
• mdl: MFCD08752227
• 分子量: 312.206
• InChiKey: YSAAGRAKROVFRY-UHFFFAOYSA-N

物化性质

• 沸点：
  382.4±42.0 °C(Predicted)
• 密度：
  1.353±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: tert-Butyl 5-bromo-3,4-dihydroisoquinoline-2(1h)-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: tert-Butyl 5-bromo-3,4-dihydroisoquinoline-2(1h)-carboxylate
CAS number: 215184-78-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H18BrNO2
Molecular weight: 312.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-3,4-二氢-1H-异喹啉-2-羧酸叔丁酯 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 5-溴-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  [EN] KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE

  摘要：

  本文披露了蛋白激酶抑制剂，特别是Bruton氏酪氨酸激酶（BTK）抑制剂，包括它们的制剂、制备过程以及利用这些蛋白激酶抑制剂治疗或预防与激酶功能相关的疾病、疾病和症状的用途。具体来说，本发明涉及选择性BTK抑制剂。

  公开号：

  WO2021207549A1
• 作为产物：
  描述：

  邻溴氰苄 在 硼烷四氢呋喃络合物 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 甲酸 、 二氯甲烷 为溶剂， 反应 95.5h， 生成 5-溴-3,4-二氢-1H-异喹啉-2-羧酸叔丁酯
  参考文献：
  名称：

  一系列含氮杂环的新型GPR40激动剂的设计，合成和生物学评价

  摘要：

  通过在TAK-875的末端苯环上引入含氮杂环，以降低其亲脂性，设计了一系列新的GPR40激动剂。研究了三种不同的β-取代苯基丙酸作为酸性组分。总共合成了34种化合物，其中化合物30在体外具有与TAK-875相当的GPR40激动活性，并且通过计算得出相对较低的亲脂性（30，EC 50  = 1.2μM，cLogP = 1.3; TAK-875：EC 50  = 5.1μM，cLogP = 3.4）。此外，化合物30能增强从正常ICR小鼠中分离的原胰岛的胰岛素分泌，并在体外对细胞色素P450没有明显的抑制作用。在体内，化合物30在正常ICR小鼠的口服葡萄糖耐量试验（oGTT）中显示出功效。

  DOI：

  10.1016/j.bmcl.2018.07.048

文献信息

• Photocatalyzed Csp³–Csp³ cross-dehydrogenative coupling of <i>N</i>-Boc-tetrahydroisoquinolines with α,β-unsaturated ketones
  作者：Na-Ri-Mei Ao、Xue-Qing Zhu、Chun-Xin Zhao、Ya-Ru Gao、Yong-Qiang Wang

  DOI：10.1039/d1ob00527h

  日期：——

  A novel photocatalyzed cross-dehydrogenative coupling reaction of N-Boc-tetrahydroisoquinolines with α,β-unsaturated ketones has been developed. This research provides an easy access to a variety of C1-substituted tetrahydroisoquinolines, which can be further transformed into benzo[a]-quinolizine-2-ones, the skeletons of natural products with a wide range of biological activities. The load of the photocatalyst

  开发了一种新型光催化N -Boc-四氢异喹啉与 α,β-不饱和酮的交叉脱氢偶联反应。这项研究提供了一种容易获得各种 C1 取代的四氢异喹啉的方法，这些四氢异喹啉可以进一步转化为具有广泛生物活性的天然产物骨架苯并[ a ]-quinolizine-2-ones。光催化剂的负载量低，氧化剂便宜且毒性较小。
• [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS<br/>[FR] COMPOSÉS TÉTRAHYDROISOQUINOLINES SUBSTITUÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013055984A1

  公开（公告）日：2013-04-18

  The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

  本发明提供了化合物的公式(I)：或其立体异构体，以及其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是XIa因子和/或血浆激肽酶的抑制剂，可用作药物。
• [EN] HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE<br/>[FR] COMPOSÉS HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020207991A1

  公开（公告）日：2020-10-15

  The present invention relates to compounds of formula (I), wherein R1 to R3, n and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

  本发明涉及式(I)的化合物，其中R1至R3，n和A如本文所述，以及其药学上可接受的盐，以及包括这些化合物的组合物和使用这些化合物的方法。
• [EN] S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING<br/>[FR] AGONISTES DE S1P1 COMPRENANT UN CYCLE AZOTÉ BICYCLIQUE
  申请人：GLAXO GROUP LTD

  公开号：WO2010146105A1

  公开（公告）日：2010-12-23

  The present invention relates to novel compounds of formula (I) having S1P1 agonist activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有S1P1激动剂活性的式(I)新化合物，其制备方法，包含它们的药物组合物及其用于治疗各种疾病的应用。
• [EN] SULFAMIDE SODIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS SULFAMIDES DES CANAUX DE SODIUM
  申请人：AMGEN INC

  公开号：WO2013134518A1

  公开（公告）日：2013-09-12

  The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供了式I的化合物或其药学上可接受的盐，这些化合物是电压门控钠通道的抑制剂，特别是Nav 1.7。这些化合物对于治疗通过抑制钠通道可治疗的疾病，如疼痛障碍，是有用的。还提供了含有本发明化合物的药物组合物。